The Discovery and Applications of Dulaglutide for Type 2 Diabetes and Other Potential Uses
DOI:
https://doi.org/10.58445/rars.762Keywords:
Dulaglutide, Type 2 Diabetes, TrulicityAbstract
This paper discusses the function of dulaglutide (Trulicity), a glucagon-like peptide-1 (GLP-1) receptor agonist, in treating type 2 diabetes mellitus (T2DM). Dulaglutide’s mechanism of action and efficacy in treating cardiovascular diseases have gained the drug FDA-approval as a multi-purpose medication in comparison to other GLP-1 receptor agonists on the market. This analysis underscores the pharmacotoxicology profile of dulaglutide and offers comprehensive information on the cautious consideration needed in prescribing the injection to T2DM patients.
References
W. E. Contributors, “Type 2 Diabetes,” WebMD. Accessed: Nov. 23, 2023. [Online]. Available: https://www.webmd.com/diabetes/type-2-diabetes
“What Is Diabetes? - NIDDK,” National Institute of Diabetes and Digestive and Kidney Diseases. Accessed: Nov. 25, 2023. [Online]. Available: https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes
Y. Wu, Y. Ding, Y. Tanaka, and W. Zhang, “Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention,” Int. J. Med. Sci., vol. 11, no. 11, pp. 1185–1200, Sep. 2014, doi: 10.7150/ijms.10001.
“Insulin Resistance: What It Is, Causes, Symptoms & Treatment.” Accessed: Nov. 25, 2023. [Online]. Available: https://my.clevelandclinic.org/health/diseases/22206-insulin-resistance
“Dr. John Eng’s Research Found That The Saliva Of The Gila Monster Contains A Hormone That Treats Diabetes Better Than Any Other Medicine.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.diabetesincontrol.com/dr-john-engs-research-found-that-the-saliva-of-the-gila-monster-contains-a-hormone-that-treats-diabetes-better-than-any-other-medicine/
J. Li, S. Wei, C. Cao, K. Chen, H. He, and G. Gao, “Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines,” Electron. J. Biotechnol., vol. 41, pp. 56–59, Sep. 2019, doi: 10.1016/j.ejbt.2019.07.002.
“Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes - Clinical Trials Arena.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.clinicaltrialsarena.com/projects/trulicity-type-2-diabetes/
A. M. Thompson and J. M. Trujillo, “Advances in the treatment of type 2 diabetes: impact of dulaglutide,” Diabetes Metab. Syndr. Obes. Targets Ther., vol. 9, pp. 125–136, May 2016, doi: 10.2147/DMSO.S75452.
“Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease | Eli Lilly and Company.” Accessed: Nov. 25, 2023. [Online]. Available: https://investor.lilly.com/news-releases/news-release-details/trulicityr-dulaglutide-first-and-only-type-2-diabetes-medicine
“Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166864/
“National Diabetes Statistics Report | Diabetes | CDC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.cdc.gov/diabetes/data/statistics-report/index.html
CDC, “By the Numbers: Diabetes in America,” Centers for Disease Control and Prevention. Accessed: Nov. 25, 2023. [Online]. Available: https://www.cdc.gov/diabetes/health-equity/diabetes-by-the-numbers.html
M. E. Cerf, “Beta Cell Dysfunction and Insulin Resistance,” Front. Endocrinol., vol. 4, p. 37, Mar. 2013, doi: 10.3389/fendo.2013.00037.
“Islets of Langerhans - an overview | ScienceDirect Topics.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/islets-of-langerhans
R. Outreach, “A focus on beta cell mass could help prevent type 2 diabetes,” Research Outreach. Accessed: Nov. 25, 2023. [Online]. Available: https://researchoutreach.org/articles/focus-beta-cell-mass-could-help-prevent-type-2-diabetes/
“Insulin and Insulin Resistance - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1204764/
P. V. Röder, B. Wu, Y. Liu, and W. Han, “Pancreatic regulation of glucose homeostasis,” Exp. Mol. Med., vol. 48, no. 3, p. e219, Mar. 2016, doi: 10.1038/emm.2016.6.
L. I. Hudish, J. E. B. Reusch, and L. Sussel, “β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes,” J. Clin. Invest., vol. 129, no. 10, pp. 4001–4008, Oct. 2019, doi: 10.1172/JCI129188.
“Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370947/
J. Kelly, M. Karlsen, and G. Steinke, “Type 2 Diabetes Remission and Lifestyle Medicine: A Position Statement From the American College of Lifestyle Medicine,” Am. J. Lifestyle Med., vol. 14, no. 4, pp. 406–419, Jun. 2020, doi: 10.1177/1559827620930962.
V. Jacobbi, “Mayo study uses electronic health record data to assess metformin failure risk, optimize care,” Mayo Clinic News Network. Accessed: Nov. 25, 2023. [Online]. Available: https://newsnetwork.mayoclinic.org/discussion/mayo-study-uses-electronic-health-record-data-to-assess-metformin-failure-risk-optimize-care/
“Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896253/
W. Latif, K. J. Lambrinos, and R. Rodriguez, “Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs),” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2023. Accessed: Nov. 25, 2023. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK572151/
M. Sanford, “Dulaglutide: first global approval,” Drugs, vol. 74, no. 17, pp. 2097–2103, Nov. 2014, doi: 10.1007/s40265-014-0320-7.
“KEGG DRUG: Dulaglutide.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.kegg.jp/entry/D09889
A. P. Davenport, C. C. G. Scully, C. de Graaf, A. J. H. Brown, and J. J. Maguire, “Advances in therapeutic peptides targeting G protein-coupled receptors,” Nat. Rev. Drug Discov., vol. 19, no. 6, Art. no. 6, Jun. 2020, doi: 10.1038/s41573-020-0062-z.
L. B. Knudsen and J. Lau, “The Discovery and Development of Liraglutide and Semaglutide,” Front. Endocrinol., vol. 10, p. 155, Apr. 2019, doi: 10.3389/fendo.2019.00155.
J. L. Górriz et al., “GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists,” J. Clin. Med., vol. 9, no. 4, p. 947, Mar. 2020, doi: 10.3390/jcm9040947.
L. L. Smith, J. F. Mosley, C. Parke, J. Brown, L. S. Barris, and L. D. Phan, “Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist,” Pharm. Ther., vol. 41, no. 6, pp. 357–360, Jun. 2016.
“Mechanisms of Action of GLP-1 in the Pancreas - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1934514/
“ATP-sensitive potassium channelopathies: focus on insulin secretion - PMC.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1180549/
R. Carlessi et al., “GLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activation,” Sci. Rep., vol. 7, p. 2661, Jun. 2017, doi: 10.1038/s41598-017-02838-2.
L. E. Fridlyand and L. H. Philipson, “Glucose sensing in the pancreatic beta cell: a computational systems analysis,” Theor. Biol. Med. Model., vol. 7, p. 15, May 2010, doi: 10.1186/1742-4682-7-15.
“FDA Approves TrulicityTM (dulaglutide), Lilly’s Once-Weekly Therapy for Adults with Type 2 Diabetes | Eli Lilly and Company.” Accessed: Nov. 25, 2023. [Online]. Available: https://investor.lilly.com/news-releases/news-release-details/fda-approves-trulicitytm-dulaglutide-lillys-once-weekly-therapy
A. Baker Khan, A. Shah, S. Ahmad, M. I. Khan, and A. Amir, “Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report,” Cureus, vol. 15, no. 5, p. e38630, doi: 10.7759/cureus.38630.
“Ozempic or Trulicity: Which Should You Take for Diabetes? - GoodRx.” Accessed: Nov. 25, 2023. [Online]. Available: https://www.goodrx.com/classes/glp-1-agonists/ozempic-vs-trulicity
“Sharon Osbourne Says She Lost Too Much Weight Taking Ozempic,” Healthline. Accessed: Nov. 25, 2023. [Online]. Available: https://www.healthline.com/health-news/sharon-osbourne-stopped-taking-ozempic-because-she-lost-too-much-weight
“Ozempic vs. Trulicity: Is one of them right for you?” Accessed: Nov. 25, 2023. [Online]. Available: https://www.medicalnewstoday.com/articles/drugs-ozempic-vs-trulicity
Downloads
Posted
License
Copyright (c) 2023 Carol Zhang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.